1b0a23c2-785d-4a14-b673-86c97ceff401
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- PROTEIN_SECRETION+0.400
- DNA_REPAIR+0.300
- MYC_TARGETS_V2+0.300
- MTORC1_SIGNALING+0.200
- MYC_TARGETS_V1+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- HEDGEHOG_SIGNALING-0.500
- APICAL_JUNCTION-0.400
- HYPOXIA-0.400
- KRAS_SIGNALING_UP-0.400
- MYOGENESIS-0.400
- ADIPOGENESIS-0.300
- COAGULATION-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 87dc0bab-b318-47ec-a9a3-819a7388e731 | — | — | 0.878 |
| 2 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.874 |
| 3 | 223494f1-6c0b-446e-998d-53b3b4d0da1a | — | — | 0.859 |
| 4 | MBCProject_0454_T1_RNA | — | B | 0.857 |
| 5 | C3N-04382 | — | cohortMD1 | 0.856 |
| 6 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.843 |
| 7 | MNG274 | — | — | 0.834 |
| 8 | SRR11296816 | — | — | 0.831 |
| 9 | MBCProject_4278_T3_RNA | — | C | 0.826 |
| 10 | s0122212 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |